AMPER Proof of Concept Study

Launched by UNIVERSITY OF STRATHCLYDE · Mar 19, 2025

Keywords

ClinConnect Summary

The AMPER Proof of Concept Study is a clinical trial designed to help improve memory and quality of life for people living with Alzheimer's disease. This study will test a special app called the AMPER system, which features an animated character that helps users reminisce about their past by sharing personalized stories, images, and videos. The goal is to see if using a personalized version of the app can enhance memory recall and the overall experience of reminiscing compared to a non-personalized version. Participants will use the app at home with the support of a caregiver for 12 weeks, and their progress will be tracked through regular feedback and app usage data.

To participate in this study, individuals should be at least 50 years old and diagnosed with mild to moderate Alzheimer's disease. They need to have a caregiver who can help them throughout the process. However, those with certain other neurological conditions or significant psychiatric issues won't be eligible. By the end of the study, researchers hope to gather valuable feedback that will help improve the AMPER system and potentially create a helpful tool for many people affected by Alzheimer's in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • - Diagnosis of probable Alzheimer's disease of mild to moderate severity according to DSM-IV (Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition) and NINCS-ADRAD (National Institute of Neurological and Communicative Disorders and Stroke-Alzheimer's Disease and Related Disorders Association) criteria.
• • Age 50 or older
• • Sensory (visual and auditory), language, and physical abilities adequate to perform assessments (corrective aids allowed).
• • ACE III score between 20 and 82 (inclusive) (or equivalent score on MMSE (between 14 and 24, based on Law et al., 20123 equivalence data) or MOCHA (between 14 and 24 (based on Pendleberry et al., 2011 equivalence data).
• • Having a caregiver or family member who can attend all visits, perform assessments, and supervise administration of study.
• Exclusion Criteria:
• • Medical records indicate AD patients with the visual variant or having colour vision deficits.
• • Medical records indicate a CT or MRI within 24 months prior to screening that indicates a diagnosis other than probable Alzheimer's disease.
• • Medical records indicate any significant neurological disease other than probable AD (e.g. Parkinson's disease, Huntington's disease, brain tumor, normal pressure hydrocephalus, progressive supranuclear palsy, seizure disorder, subdural hematoma, multiple sclerosis, history of stroke, or history of head injury requiring hospitalization).
• • On review of medical records, no clinically significant abnormal findings on previous physical examination, medical history, or clinical laboratory results that would indicate an alternative diagnosis.
• • Current history of major psychiatric disorder (e.g. Major depression) (as indicated on medical records)
• • History of substance misuse (as indicated on medical records).